December 2025

Welcome to the December 2025 Lymphoma Australia Newsletter

Inside this edition we cover the following topics:

  • Season’s Greetings from our CEO
  • Celebrating our community: $391,532 raised in 2025
  • Looking ahead to 2026 events and advocacy
  • Upcoming in-person and online support groups
  • New webinar recordings: CNS, MZL, and Mantle Cell Lymphoma
  • PBS listing updates for new treatments
  • Understanding Bispecific Antibodies
  • Sponsor recognition and Holiday Donation Appeal
  • Help shape the future: CLL & SLL patient survey
  • Welcoming our new Specialist Lymphoma Care Nurse
  • Managing side-effects and mental health over the holiday break

CLICK HERE to read the newsletter

Contact Lymphoma Australia Today!

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.